Institutional dossier
The documented history of Bristol Myers Squibb: chronology, people, research, capital and compute, and governance. Every statement opens its source and its limits.
Records dated 2020-10-28 to 2020-10-28 · 0 undated
1 claims · 1 sources · 1 not editorially accepted. The counts describe this selection. They do not measure completeness or independent confirmation.
Scope, evidence and limits
Description: Pharmaceutical company (NYSE: BMY).
The records are grouped automatically. No human inspection of the selected claims, source paths or framing is recorded for this dossier. Each source passage shows how it was checked.
The dossier is computed from existing records. It is not a continuous history of the institution, and a missing record does not mean that an event or relationship did not happen. The chronology uses the dates of events and reports, not the date the public could first have known of them. Later sources can describe earlier events.
Select any statement to see its exact claim, qualification, date note, evidence passage, location in the source, source version and review status. The description above is Selekoa’s stored description of the institution, based on these sources:
Chronology
Records about the institution itself and documented changes to its frameworks, by year. Expand a year to read the claims. People’s other institutional records and related documents have their own sections. Where a date gives only the year or month, the order within it is unknown.
2020Record year · 1 claims
- insitro announced on 28 October 2020 a collaboration with Bristol Myers Squibb, stating a $50 million upfront payment, eligibility for $20 million in near-term operational milestones and up to an aggregate of more than $2 billion in discovery, development, regulatory and commercial milestones.insitro → announced a partnership with → Bristol Myers SquibbInspect claim & evidence ↗
Record about this institution · Stated in source · Supported Announced
Activity: announced
Qualification and date notes
Announced terms as insitro states them. The milestone amounts are "up to" and conditional; they are not payments, and the headline "total potential deal value" is not recorded as a value received.
Date of insitro's release.